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Background: We have recently reported on the changes in plasma free amino acid (PFAA) profiles in lung cancer
patients and the efficacy of a PFAA-based, multivariate discrimination index for the early detection of lung cancer.
In this study, we aimed to verify the usefulness and robustness of PFAA profiling for detecting lung cancer using
new test samples.
Methods: Plasma samples were collected from 171 lung cancer patients and 3849 controls without apparent
cancer. PFAA levels were measured by high-performance liquid chromatography (HPLC)–electrospray ionization
(ESI)–mass spectrometry (MS).
Results: High reproducibility was observed for both the change in the PFAA profiles in the lung cancer patients
and the discriminating performance for lung cancer patients compared to previously reported results. Furthermore,
multivariate discriminating functions obtained in previous studies clearly distinguished the lung cancer patients
from the controls based on the area under the receiver-operator characteristics curve (AUC of ROC = 0.731 ~ 0.806),
strongly suggesting the robustness of the methodology for clinical use. Moreover, the results suggested that the
combinatorial use of this classifier and tumor markers improves the clinical performance of tumor markers.
Conclusions: These findings suggest that PFAA profiling, which involves a relatively simple plasma assay and
imposes a low physical burden on subjects, has great potential for improving early detection of lung cancer.
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Several minimally invasive, easy-to-use cancer diagnostic
methods using peripheral blood samples have recently
been developed to ease the physical burden on patients
and to reduce cost and time [1-3]. Computer-aided sys-
tems for data mining, (e.g., using multivariate analysis) are
now readily available and have shown promising results
when applied to metabolic profiles for diagnostic and cli-
nical use [4-6]. Several applications using metabolome* Correspondence: mshingyoji@chiba-cc.jp; akira_imaizumi@ajinomoto.com
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reproduction in any medium, provided the oranalysis based on machine learning to diagnose human
cancer using peripheral blood or urine have recently been
demonstrated [7-12].
Among metabolites, amino acids are one of the most
suitable candidates for focused metabolomics because they
are either ingested or synthesized endogenously and play
essential physiological roles both as basic metabolites and
metabolic regulators. To measure amino acids, plasma free
amino acids (PFAAs), which are abundant in the circulation
and link all organ systems, are favorable targets because
PFAA profiles are influenced by metabolic variations in
specific organ systems induced by specific diseases [13-18].
Furthermore, several investigators have reported changes in
PFAA profiles in cancer patients, including lung cancer
patients [19-27]. However, several discrepancies existal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the data set [22].
High-throughput techniques using high-performance
liquid chromatography (HPLC)– electrospray ionization
(ESI)–mass spectrometry (MS) to measure amino acids
with sufficient accuracy for clinical use have also recently
been developed [28-31].
By combining these technologies, we recently obtained
preliminary data on the efficacy of a diagnostic index
based on PFAA concentrations, known as the “Amino-
Index technology”, which compresses multidimensional
information from PFAA profiles into a single dimension
and maximizes the differences between patients and con-
trols. This technology was shown to be useful in the early
detection of colorectal, breast, and lung cancers in ap-
proximately 150 samples from a single medical institute
[32,33]. Furthermore, we also verified the efficacy and sta-
tistical robustness of this method using larger sample sizes
from multiple medical institutes and developed discrimi-
nating functions to detect five types of cancer, including
lung, gastric, colorectal, breast, and prostate cancer
[34,35]. We also found that changes in PFAA profiles that
were common to all types of cancer as well as those spe-
cific to individual cancers [34] .These functions are used
in the “AminoIndexW Cancer Screening” service in Japan.
Lung cancer has been the leading cause of cancer
death since 1998, and in Japan, >60,000 patients have
died from lung cancer since 2005 [36]. Conventionally,
chest X-rays and sputum cytology are used to screen for
lung cancer in patients in Japan. However, neither chest
X-rays nor sputum cytology are ideal or versatile enough
to detect early lung cancer. Although chest X-rays are
useful for detecting peripheral lung cancer, this method
is not always suitable for early detection [37]. In
addition, this technique requires highly skilled techni-
cians to achieve sufficient accuracy. Sputum cytology
has been reported to be useful only for the detection of
squamous cell carcinoma and is inadequate for detecting
adenocarcinoma (which is the major histological type of
lung cancer in Japan) or for detecting lung cancer in
asymptomatic non-smokers [37].
Compared to chest X-ray and sputum cytology, a PFAA-
based diagnostic method would be easier to use because it
involves a relatively simple plasma assay, imposes a lower
physical burden on patients and does not require
advanced technical skills. Moreover, this method can also
detect lung cancer regardless of cancer stage and histo-
logical type, including small cell lung cancer [32,34,35].
In this study, we aimed to verify the usefulness of PFAA
profiling for lung cancer detection using samples that had
never been used as a data set to derive discriminating
functions. As a result, highly reproducible results were
observed in both the PFAA profiles and the discriminating
performance of previously obtained PFAA-based, multiplexdiscriminant functions, suggesting the robustness of PFAA
profiling for the early detection of lung cancer.
Methods
Ethics
The study was conducted in accordance with the Decla-
ration of Helsinki, and the protocol was approved by the
ethics committees of the Chiba Cancer Center, the Osaka
Medical Center for Cancer and Cardiovascular Diseases,
the Gunma Prefectural Cancer Center, the Kanagawa
Health Service Association, the Kameda Medical Center
Makuhari, and the Mitsui Memorial Hospital. All subjects
gave their written informed consent for inclusion before
participating in the study. All data were analyzed anony-
mously throughout the study.
Subjects
The participants in this study consisted of Japanese
patients who had previously been histologically diagnosed
with lung cancer at the Chiba Cancer Center (n=171)
between 2007 and 2009. Control subjects (n=3849) with-
out apparent cancers who were undergoing comprehen-
sive medical examinations at the Kanagawa Health Service
Association, the Kameda Medical Center Makuhari, or the
Mitsui Memorial Hospital, Japan between 2008 and 2010
were recruited to participate in the study. Among the
participants, 85 cancer patients (P1) and 421 gender- and
age-matched controls (C1) were used as the study data-
set for two preliminary studies (Table 1) [32,34]. The
remaining 86 cancer patients (P2) and 323 gender- and
age-matched controls (C2) were used as a test dataset and
were not used to derive the discriminating functions in pre-
vious studies (Table 1) [32,34]. The remaining 3427 un-
matched controls (C3) were also included and were not
used to derive the discriminating functions in previous
studies (Table 1) [32,34].
Using these subjects, four data sets were evaluated in
this study. Dataset 1 includes P1 and C1, Dataset 2
includes P2 and C2, Dataset 3 includes all of the subjects
involved in this study (P1, P2, C1, C2, and C3), and
Dataset 4 includes all of the patients involved in this
study (P1 and P2) (Table 1).
Measurement of plasma amino acid concentration
Blood samples (5 ml) were collected from forearm veins,
after overnight fasting, in tubes containing ethylenedia-
minetetraacetic acid (EDTA; Termo, Tokyo, Japan) and
were immediately placed on ice. Plasma was prepared by
centrifugation at 3,000 rpm and 4°C for 15 min and
stored at −80°C until analysis. The plasma samples were
deproteinized using acetonitrile at a final concentration
of 80% before measurement. The amino acid concentra-
tions in the plasma were measured by HPLC–ESI–MS
followed by precolumn derivatization. The analytical
Table 1 Demographic and clinical characteristics of the subjects
Subjects Patients Controls
Subgroup P1 P2 C1 C2 C3
Dataset 1 Used Used
2 Used Used
3 Used Used Used Used Used
4 Used Used
Number Total 85 86 421 323 3104
(Male, Female) (49,36) (68,18) (245,176) (263,60) (1898,1206)
Age, y Mean (SD) 65.1 (9.7) 67.8 (8.2) 63.1 (8.7) 61.9 (6.0) 49.4 (8.0)
Range 30-90 41-83 28-86 37-88 23-67
BMI Mean (SD) 22.1 (3.7) 22.4 (3.2) 22.8 (3.0) 23.4 (2.9) 23.2 (3.3)
Range 14.6~31.2 15.7-34.6 14.2-37.1 16.9-35.4 14.8-41.2
Smoking status Never 26 18 222 139 1865
Ex 29 36 106 107 434
Current 29 29 57 62 695
Unknown 1 3 36 15 110





Histology Adenocarcinoma 59 55
Squamous cell carcinoma 13 12
Other NSCLC 5 8
SCLC 8 11
a: Cancer stages were determined according to the International Union Against Cancer TNM Classification of Malignant Tumors, 6th Edition [38].
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Among the 20 genetically encoded amino acids, gluta-
mate (Glu), aspartate (Asp), and cysteine (Cys) were
excluded from the analysis because they are unstable in
blood. Citrulline (Cit) and ornithine (Orn) were mea-
sured instead because they are relatively abundant in
blood and are known to play important roles in metabol-
ism. The following 19 amino acids were measured and
analyzed: alanine (Ala), arginine (Arg), asparagine (Asn),
Cit, glutamine (Gln), glycine (Gly), histidine (His), iso-
leucine (Ile), leucine (Leu), lysine (Lys), methionine
(Met), Orn, phenylalanine (Phe), proline (Pro), serine
(Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr),
and valine (Val). The concentrations of amino acids
in the plasma were expressed as μM values. For ana-
lysis of the PFAA profile, two measurements were
conducted for each of the 19 amino acids. The absolute
concentration of each amino acid and the ratios of the
amino acid concentrations expressed by the follow
equation as previously described were used [32,34]. The
concentrations of the amino acids in the plasma were




where X2i,j is the ratio of the amino acid concentration of
the j-th amino acid of the i-th subject, and Xi,j is the plasma
concentration (μM) of the j-th amino acid of the i-th subject.
Measurement of tumor markers
Using serum samples from lung cancer patients, the levels
of the following five tumor markers were measured: CEA
(chemiluminescence immunoassay, normal range ≦ 5.0 ng/
ml), CYFRA (electrochemiluminescence immunoassay,
normal range ≦ 3.5 ng/ml), ProGRP (enzyme-linked
immunoadsorbent assay, normal range ≦ 46 pg/ml), SCC
(enzyme immunoassay, normal range ≦ 1.5 ng/ml), and
NSE (radioimmunoassay, normal range ≦ 10 ng/ml) [39].
Calculation of discriminant scores
The PFAA profiles of subjects were substituted into the
discriminating functions obtained from the results of
Figure 1 PFAA profiles of lung cancer patients. Axes show the AUC of the ROC for each amino acid to discriminate lung cancer patients from
controls. Black bold lines indicate the point at which the AUC of the ROC = 0.5.
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Discriminant- 1 and Discriminant- 3 were logistic regres-
sion functions, whereas Discriminant- 2 was a linear
discriminating function using plasma concentrations
(expressed in μM) as explanatory variables.
Statistical analysis
Mean and SD
The mean amino acid concentrations ± standard devia-
tions (SD) were calculated to determine the overall
PFAA profiles for both patients and controls.
Mann–Whitney U-test
The Mann–Whitney U-test was used to evaluate differ-
ences in the PFAA profiles between the patient and con-
trol samples.
ROC curve analysis
Receiver-operator characteristic (ROC) curve analyses were
performed to determine the abilities of both the PFAA
concentrations and discriminating scores to discriminate
between patients and controls. The patient labels were
fixed as positive class labels. The 95% confidence interval
(95% CI) for the AUC of ROC for the discrimination of
patients based on amino acid concentrations and ratios was
also estimated as described by Hanley and McNeil [40].
Pearson’s correlation coefficients
Pearson’s correlation coefficients were calculated among
three kinds of discriminant scores (obtained from
Discriminant- 1, Discriminant- 2, and Discriminant-
3) using Dataset 3. In addition, coefficients were also
calculated using stratified data (patients and controls).
Determination of sensitivity
The cutoff value for Discriminant- 3 was previously deter-
mined so that 95% specificity would be obtained [35]. The
sensitivity of Discriminant- 3 was also calculated as theratio of true positives to the summation of the true posi-
tives and false negatives. For tumor markers, sensitivities
were also determined as the ratio of the number of subjects
in which the marker levels were higher than the previously
determined normal range to the number of measured
subjects.
McNemar test
The McNemar test was performed to evaluate the im-
provement in sensitivities through combinatorial use of
both Discriminant- 3 and the tumor markers.
Software
All of the analyses were performed using MATLAB (The
Mathworks, Natick, MA) and GraphPad Prism (GraphPad
Software, La Jolla, CA).
Results
Characteristics of the patients and control subjects
Table 1 summarizes the characteristics of the subjects in
this study. No significant differences in body mass index
(BMI) were observed between patients and matched
controls (Table 1). Weight loss due to malnutrition was
therefore not expected to influence the results. Although
significant differences in average age were observed be-
tween the data sets, the effects appeared to be relatively
minor because the absolute values of these differences
were small (Table 1). Disease stages were determined
according to the Sixth Edition of the International
Union Against Cancer (UICC) Tumor–Node–Metastasis
(TNM) Classification of Malignant Tumors [38]. The
fractions of patients at each stage according to the type
of cancer were as follows: ~40% stage I, ~5% stage II,
~30% stage III, and ~25% stage IV (Table 1).
The cancer patients were also further subdivided based
on histological tumor type; approximately 65% of the
patients were classified as having adenocarcinoma, 15%




P1 C1 P2 C2
Mean SD Mean SD AUCa Mean SD Mean SD AUCa pb
Thr 115.8 30.8 118.5 23.6 0.453 122.6 32.0 121.8 25.8 0.483
Ser 107.8 20.8 108.8 18.1 0.472 110.7 20.1 106.7 17.4 0.560
Asn 42.6 7.3 45.2 6.5 0.383 p<0.001 47.9 11.2 46.1 6.5 0.533
Gln 547.4 71.4 586.9 64.2 0.347 p<0.001 577.5 84.1 587.1 61.5 0.470
Pro 141.6 37.1 132.3 38.4 0.588 p<0.05 157.3 48.5 138.6 38.5 0.630 p<0.001
Gly 214.3 66.2 209.7 52.2 0.490 208.0 63.5 203.5 47.9 0.511
Ala 324.2 84.5 343.1 74.8 0.428 <p0.05 366.5 99.8 353.5 69.7 0.550
Cit 29.0 8.8 33.0 7.4 0.367 p<0.001 33.3 10.3 32.4 7.1 0.530
Val 215.1 43.1 220.5 39.7 0.453 242.1 43.2 230.0 37.2 0.578 p<0.05
Met 24.2 5.4 25.8 4.6 0.388 p<0.01 26.9 7.2 26.8 4.1 0.489
Ile 64.7 16.2 60.8 14.4 0.563 73.9 14.0 64.4 13.1 0.689 p<0.001
Leu 117.6 25.3 118.8 23.8 0.484 135.2 26.3 125.2 21.3 0.610 p<0.01
Tyr 65.9 15.0 65.2 12.5 0.503 71.9 15.9 67.3 10.9 0.579 p<0.05
Phe 59.5 9.9 59.6 9.4 0.496 66.5 12.8 61.3 7.9 0.625 p<0.001
His 69.7 12.5 80.2 9.5 0.255 p<0.001 74.1 15.8 81.2 9.4 0.383 p<0.001
Trp 51.3 11.0 57.0 8.8 0.338 p<0.004 56.4 13.4 59.6 8.9 0.432
Orn 55.2 13.2 51.7 12.6 0.581 p<0.05 61.7 16.4 51.7 10.4 0.696 p<0.001
Lys 183.9 32.7 189.1 30.4 0.450 195.7 37.7 191.6 27.7 0.535
Arg 93.1 20.7 95.1 16.8 0.460 100.4 24.7 96.4 15.1 0.551
B. Ratio
Thr 4.556 0.887 4.544 0.706 0.488 4.460 0.749 4.590 0.781 0.445
Ser 4.301 0.765 4.200 0.669 0.528 4.080 0.601 4.044 0.617 0.521
Asn 1.692 0.218 1.740 0.197 0.408 p<0.01 1.749 0.235 1.742 0.194 0.494
Gln 21.800 2.097 22.661 2.233 0.383 p<0.001 21.276 2.079 22.253 2.053 0.364 p<0.001
Pro 5.599 1.246 5.049 1.225 0.654 p<0.001 5.756 1.504 5.213 1.211 0.622 p<0.001
Gly 8.543 2.566 8.102 1.994 0.542 7.608 1.872 7.703 1.734 0.477
Ala 12.715 2.141 13.123 2.156 0.459 13.253 2.380 13.321 2.092 0.499
Cit 1.150 0.328 1.278 0.288 0.378 p<0.001 1.211 0.311 1.229 0.263 0.469
Val 8.530 1.294 8.454 1.109 0.510 8.925 1.267 8.696 1.198 0.563
Met 0.955 0.128 0.990 0.115 0.407 p<0.01 0.979 0.152 1.011 0.108 0.424 p<0.05
Ile 2.558 0.519 2.321 0.405 0.631 p<0.001 2.727 0.441 2.427 0.415 0.698 p<0.001
Leu 4.657 0.760 4.547 0.643 0.551 4.986 0.795 4.731 0.671 0.607 p<0.01
Tyr 2.616 0.495 2.503 0.368 0.560 2.644 0.455 2.543 0.335 0.567
Phe 2.374 0.370 2.295 0.291 0.557 2.470 0.492 2.322 0.272 0.572 p<0.05
His 2.769 0.395 3.091 0.291 0.245 p<0.001 2.702 0.355 3.074 0.295 0.213 p<0.001
Trp 2.034 0.348 2.197 0.301 0.351 p<0.001 2.057 0.373 2.260 0.313 0.338 p<0.001
Orn 2.195 0.482 1.984 0.413 0.631 p<0.001 2.298 0.674 1.955 0.353 0.662 p<0.001
Lys 7.278 0.809 7.265 0.834 0.507 7.169 0.760 7.241 0.824 0.485
Arg 3.680 0.568 3.657 0.525 0.519 3.650 0.550 3.645 0.473 0.494
a: AUC indicates AUC of the ROC curve.
b: p value derived from the Mann–Whitney U-test.
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Table 3 Three discriminating functions and amino acids
used in each function
Discriminant Amino acids incorporated into the model Reference
1 Ala, Val, Ile, His, Trp, Orn [32]
2 Ser, Gln Pro, Cit, Val, Ile, Phe, His, Trp, Orn [34]
3 Ser, Gln, Ala, His, Orn, Lys [35]
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small cell lung cancer (SCLC) (Table 1).
PFAA profiles of lung cancer patients
First, the PFAA profiles of the study data set in previous
studies and of the test data set, which was never used
for analysis, were used to verify the changes in PFAA
profiles observed in cancer patients. Interestingly, the
PFAA profiles of the test data set were quite similar to
those of the study data set, especially for the ratios of
the amino acid concentrations (Figure 1 and Table 2),
indicating that the alteration in PFAA profiles observed
in cancer patients is robust. Significant increases in both
the concentration and ratio of Pro and Orn and signifi-
cant decreases in His were observed in both the study
and test data sets compared to controls (Figure 1 and
Table 2). The ratios more clearly reflected the alterations
in the PFAA profile than the concentrations; the profiles
of five additional amino acids were altered in the ratio
data (Gln, Met, and His were decreased in patients, and
Ile was increased in patients), while significant changes
in concentration were detected in only one direction
(Figure 1 and Table 2).
Verification of multivariate discriminating functions
We used three different discriminating functions to distin-
guish lung cancer patients from controls (Table 3). Discri-
minant 1 was derived from the PFAA profiles of cancer
patients recruited from the Osaka Medical Center for
Cancer and Cardiovascular Diseases and controls recruited
from the Center for Multiphasic Health Testing and
Services of the Mitsui Memorial Hospital [32]. Discrimi-
nant 2 and Discriminant 3 were derived from patients from
the Osaka Medical Center for Cancer and Cardiovascular
Diseases, the Chiba Cancer Center, the Kanagawa Cancer
Center, and the Gunma Prefectural Cancer Center and
controls recruited from the Center for Multiphasic HealthTable 4 AUCs of the ROC and the 95% confidential
intervals (95% CIs) for each model
Discriminant-1 Dinscriminant-2 Discriminant-3
AUC 95% CI AUC 95% CI AUC 95% CI
Dataset 1 0.731 0.668-0.794 0.822 0.768-0.875 0.777 0.718-0.836
Dataset 2 0.797 0.738-0.856 0.775 0.714-0.836 0.761 0.700-0.823
Dataset 3 0.805 0.767-0.846 0.806 0.767-0.843 0.795 0.755-0.831Testing and Services of the Mitsui Memorial Hospital, the
Kameda Medical Center Makuhari, and the Kanagawa
Health Service Association [34,35]. Discriminant 3 is com-
mercially used in the “AminoIndexW Cancer Screening”
service in Japan (Ajinomoto, CO., Inc.) [35]. Both Discri-
minant 1 and Discriminant 3 were logistic regression mo-
dels, whereas Discriminant 2 was a linear discriminating
function. Explanatory variables used in these functions are
listed in Table 3.
Three different data sets (Dataset 1, Dataset 2, and Data-
set 3) were used to verify the performance of the discri-
minating functions (Table 4 and Figure 2). Notably, the
discrimination abilities of each data set were evaluated
using the AUC of the ROC of the discriminate score and
were found to be > 0.7 in all cases, indicating that the
discrimination functions were both reproducible and
robust using independent data sets (Figure 2, Table 4).
Specifically, AUCs for the discrimination of lung cancer
patients were estimated as follows: 0.731 (95% CI: 0.668 -
0.794) for Dataset 1, 0.822 (95% CI: 0.768 - 0.875) for
Dataset 2, and 0.777 (95% CI: 0.718 - 0.836) for Dataset 3
for Discriminant- 1; 0.797 (95% CI: 0.738 - 0.856) for
Dataset 1, 0.775 (95% CI: 0.714 - 0.836) for Dataset 2, and
0.761 (95% CI: 0.700 - 0.823) for Dataset 3 for Discrimi-
nant 2; and 0.805 (95% CI: 0.767 - 0.846) for Dataset
1, 0.806 (95% CI: 0.767 - 0.843) for Dataset 2, and 0.795
(95% CI: 0.755 - 0.831) for Dataset 3 for Discriminant
3 (Figure 2, Table 4).
Selected explanatory variables partially overlapped for the
discriminating functions (Table 3); therefore, the discrimi-
nant scores were highly mutually correlated as presented in
Table 5. The correlation coefficients were as follows: 0.609
(Discriminant- 1 and Discriminant- 2), 0.552 (Discriminant-
1 and Discriminant- 3), and 0.719 (Discriminant- 2 and
Discriminant- 3) for all of the data in Dataset 3. For the
patients in Dataset 3 (i.e., P1 and P2), the correlation coeffi-
cients were 0.559 (Discriminant- 1 and Discriminant- 2),
0.506 (Discriminant- 1 and Discriminant- 3), and 0.686
(Discriminant- 2 and Discriminant- 3), and the correlation
coefficients for the controls in Dataset 3 (i.e., C1, C2, and
C3) were 0.674 (Discriminant- 1 and Discriminant- 2),
0.645 (Discriminant- 1 and Discriminant- 3), and 0.810
(Discriminant- 2 and Discriminant- 3) (Table 5).
Combinatorial use of discriminating functions and tumor
markers
For further investigation of the clinical applicability of
PFAA profiles, the combinatorial use of both the discrimin-
ating function from PFAA profiles as explanatory variables
and existing tumor markers generally used for lung cancer
detection and monitoring (CEA, CYFRA, ProGRP, SCC,
and NSE) was assessed [39,41]. In this analysis, Dataset 4
(P1 and P2) was analyzed using discriminant scores
obtained from Discriminant- 3. Subgroup analysis was also
Figure 2 ROC curves of discriminating scores for each discriminating function. Black lines indicate the ROC curves of Dataset 1, blue lines
indicate those of Dataset 2, and red lines indicate those of Dataset 3.
Shingyoji et al. BMC Cancer 2013, 13:77 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/77performed using patient data stratified into cancer stages
(stages I and II). For all patients, significantly higher
sensitivities were observed upon combinatorial use of
Discriminant- 3 and the tumor markers than upon single
use of either Discriminant- 3 or the tumor markers
(Figure 3). Similar results were observed among stage I and
II patients using the combination of Discriminant- 3 and
three tumor markers (CEA, SCC, and NSE), while no sig-
nificant improvement of sensitivity was observed using
Discriminant- 3 and CYFRA or ProGRP (Figure 3). These
results suggest that the combinatorial use of Discriminant 3
and other tumor markers is effective for lung cancer detec-
tion and monitoring, and an increase in sensitivity was
indeed confirmed (Figure 3).
Among the tumor markers, CYFRA and SCC are spe-
cific to squamous cell carcinoma (SqCC), ProGRP and
NSE are specific to small cell lung cancer (SCLC), and
CEA is not specific to any particular histological type of
lung cancer [39]. Clinically, the combinatorial use of mul-
tiple independent tumor markers is effective for detecting
lung cancer. Notably, a low correlation was observed
between Discriminant 3 and the tumor markers; the
correlation coefficients were 0.304 for CEA, 0.481 forCYFRA, -0.228 for ProGRP, 0.346 for SCC, and 0.102 for
NSE (data not shown).
Discussion
In the present study, we verified the usefulness of PFAA
profiling for lung cancer detection using new independ-
ent samples that had never been used for previous ana-
lysis and a derivation of multivariate discriminating
function(s) that could distinguish lung cancer patients
from control subjects. The results were highly reprodu-
cible for the change in PFAA profiles in lung cancer
patients and highly discriminatory for lung cancer
patients, including those with early stage cancer. There-
fore, the results strongly suggest that our method is
robust enough for clinical use. Moreover, because our
method is a relatively simple plasma assay and imposes
minimal physical burden on subjects, our findings sug-
gest that PFAA profiling has great potential for improv-
ing the early detection of lung cancer.
Among the three discriminating functions, several
amino acids were used in more than one function. His
and Orn were incorporated into all of the functions, and
Ser, Gln, Ala, Val, Ile, and Trp were incorporated into
Table 5 Correlation coefficients among the discriminant scores of Dataset 3 and its subgroups obtained from three
discriminating functions
Compared with; All data Patients (P1, P2) Controls (C1, C2, C3)
Discriminant- 1 and Discriminant- 2 0.609 0.559 0.674
Discriminant- 1 and Discriminant- 3 0.552 0.506 0.645
Discriminant- 2 and Discriminant- 3 0.719 0.685 0.810
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ding to a comparison between the study and test data
sets, plasma concentrations of Pro, Ile and Orn were
higher in each data set, while the concentrations of Gln,
His and Trp were lower (Figure 1 and Table 2). Among
these amino acids, changes in the plasma concentrations
of four amino acids (Pro, Ile, His, and Orn) were identi-
cal to the changes in amino acids in lung cancer patients
in previous studies. Maeda et al. have reported that
plasma concentrations of Ser, Pro, Gly, Ala, Met, Ile,
Leu, Tyr, Phe, Orn, and Lys are increased and His is
decreased in lung cancer patients [32]. Miyagi et al. have
also reported that the plasma concentrations of Ser, Pro,
Gly, Ile, and Orn are increased, whereas Gln, Cit, His,
and Trp are decreased in lung cancer patients [34].
Therefore, the results strongly suggest the robustness of
these three discriminating functions for the detection of
lung cancer.Figure 3 Sensitivities of discriminating scores for Discriminant- 3, leve
Black bars indicate the sensitivities of all of the data from Dataset 4, while g
* : p<0.05, **: p<0.01, ***: p<0.001 significant at McNemar test.Moreover, Miyagi et al. have also reported that plasma
levels of Gln, Trp, His, Pro, and Orn are commonly
altered in cancer patients with five types of cancer (lung
cancer, gastric cancer, colorectal cancer, breast cancer,
and prostate cancer) [34]. Therefore, the data also
strongly suggest that the changes in plasma concentra-
tions of Pro, His, and Orn are essentially associated with
carcinogenesis and cancer progression regardless of the
location of the tumor.
Although tumor markers have been used extensively
to detect lung cancer and estimate clinical condition, the
markers are not always useful due to low specificity and
insufficient sensitivity. Therefore, combinatorial use of
two or more independent tumor markers is necessary
for clinical utility [39]. Our results suggest that a PFAA-
based diagnostic method would be a novel index to im-
prove the insufficient clinical performance of the tumor
markers. Combinatorial use of the tumor markers withls of tumor markers, and combinatorial use of both markers.
ray bars indicate those of patients with stage I and II disease.
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http://www.biomedcentral.com/1471-2407/13/77Discriminant- 3 showed higher sensitivities than any of the
tumor markers generally used for lung cancer patients.
Additionally, only a low correlation was observed between
the discriminating function scores and the tumor marker
levels, suggesting the independence of the PFAA profiles
from the existing tumor markers. Miyagi et al. have sug-
gested that the change in the PFAA profile in cancer
patients reflects two aspects: metabolic changes common
to many cancers and metabolic characteristics specific to
each cancer [34]. Indeed, although the results were preli-
minary, the same study demonstrated the possibility of
discriminating the cancer type. To clarify this hypothesis,
testing the behavior of the discriminating function scores in
lung cancer patients after surgery and chemotherapy and in
those with recurrence would be necessary.
Because this study was designed as a case–control study,
the results cannot be directly applied to further observation
or prediction. Therefore, additional validation using a larger
sample size is necessary to establish the clinical utility of
our approach. Nonetheless, we believe that our results
strongly suggest the clinical usefulness of the PFAA-based
diagnostic method for the detection of lung cancer.
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